Active — Not RecruitingNot Applicable

Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes

Canada60 participantsStarted 2022-07-04

Plain-language summary

Type 2 diabetes is a chronic disease that can lead to a number of complications if uncontrolled and there is a projected increase of 33% patients living with diabetes over the next 10 years. There can be improvements to modifiable risk factors such as diet and exercise, in addition to medications. Treatment often involves a multidisciplinary approach with a physician, endocrinologist, dietitian, pharmacist and other support health professionals as required. This study will evaluate the effects of the pharmacists (or pharmD interns) intervention, looking at changes to the patients HbA1C, which is a measure of the patients blood glucose control over the previous 3 months as well as the patients understanding and comfort with managing their own diabetes via participant survey.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients whose primary care physician is within the Portage Clinic * Adults (age 18 and older) with type 2 diabetes with HbA1C 10 % or above * Patients whom have not had previous clinical pharmacist directed intervention * Agree to participate in the study, including frequent follow up, blood glucose home monitoring as directed and repeat lab work * Willing to consider medication adjustments as deemed appropriate * Willing to review and sign the Research Participant Information and Informed Consent Form Exclusion Criteria: * Patients less than 18 years of age * Patients with type 1 diabetes, pre-diabetes or gestational diabetes (or whom are pregnant) * Patients whom have had recent or ongoing clinical pharmacist directed intervention or intensive health care professional monitoring and guidance * Patients with HbA1C less than 10% * Patients whom refuse medication adjustments * Patients with severe renal impairment or receiving dialysis treatments

What they're measuring

Change in Baseline Hemoglobin A1C (HbA1C) at 10 months

Timeframe: baseline and through study completion at 10 months approximately

Trial details

NCT IDNCT05442840

SponsorUniversity of Manitoba

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12